Diarrhoea and skin rash were lower than previously reported with combination oxaliplatin, fluoropyrimidine, and EGFR antibody therapy,17 probably because only 31% received panitumumab—the panitumumab comparison is still masked—and also because of the short (6-week) duration preoperative treatment. The gene discussed is EGFR; the disease is Skin rash.